HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chemokine receptor-directed agents as novel anti-HIV-1 therapies.

Abstract
Historically, therapeutic benefit in the treatment of human immunodeficiency virus infection (HIV-1) infection has been best achieved by targeting viral proteins like HIV protease involved in viral replication rather than host cell proteins, like CD4, which facilitate the process of viral infection. Two discoveries in 1996 presented a novel opportunity to redress this issue: 1) the understanding that heptahelical G-protein coupled chemokine receptors on the surface of T cells and macrophages functioned together with CD4 to mediate viral entry, and 2) the observation that CD4 positive T cells from individuals homozygous for the CCR5 delta 32 null allele were resistant to infection by macrophage-tropic strains of the virus in vitro and in vivo. Since that time, data demonstrating that selective blockade of two chemokine receptors, CCR5 and CXCR4, by small molecule chemokine receptor antagonists or receptor-directed biologics could robustly inhibit the infection of human peripheral blood mononuclear cells (PBMCs) by macrophage-tropic and T-cell line tropic strains respectively in vitro has validated this potential approach to therapy. Early clinical trial data now also confirms that these types of agents will have anti-viral activity in some HIV-1 infected individuals; however to date, dose limiting off-target activities have prohibited a full test of their potential clinical value. It also remains to be seen how these types of agents will fare in synergy with existing HIV-1 targeted antivirals, or those currently in development.
AuthorsSander G Mills, Julie A DeMartino
JournalCurrent topics in medicinal chemistry (Curr Top Med Chem) Vol. 4 Issue 10 Pg. 1017-33 ( 2004) ISSN: 1568-0266 [Print] United Arab Emirates
PMID15193136 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-HIV Agents
  • Antibodies
  • CCR5 Receptor Antagonists
  • Chemokine CCL5
  • Chemokines
  • Heterocyclic Compounds, 4 or More Rings
  • Oligopeptides
  • Receptors, CCR5
  • Receptors, CXCR4
  • Receptors, Chemokine
Topics
  • Anti-HIV Agents (chemistry, pharmacology, therapeutic use)
  • Antibodies (immunology, pharmacology, therapeutic use)
  • CCR5 Receptor Antagonists
  • Chemokine CCL5 (analogs & derivatives)
  • Chemokines (chemistry)
  • HIV Infections (drug therapy)
  • HIV-1 (drug effects)
  • Heterocyclic Compounds, 4 or More Rings (chemistry, pharmacology, therapeutic use)
  • Humans
  • Molecular Structure
  • Oligopeptides (chemistry, pharmacology, therapeutic use)
  • Receptors, CCR5 (immunology, physiology)
  • Receptors, CXCR4 (antagonists & inhibitors, immunology, physiology)
  • Receptors, Chemokine (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: